225 related articles for article (PubMed ID: 20505100)
1. Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements.
Cao X; Yasuda T; Uthayathas S; Watts RL; Mouradian MM; Mochizuki H; Papa SM
J Neurosci; 2010 May; 30(21):7335-43. PubMed ID: 20505100
[TBL] [Abstract][Full Text] [Related]
2. Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates.
Beck G; Singh A; Zhang J; Potts LF; Woo JM; Park ES; Mochizuki H; Mouradian MM; Papa SM
Proc Natl Acad Sci U S A; 2019 Sep; 116(37):18664-18672. PubMed ID: 31455727
[TBL] [Abstract][Full Text] [Related]
3. Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease.
Berton O; Guigoni C; Li Q; Bioulac BH; Aubert I; Gross CE; Dileone RJ; Nestler EJ; Bezard E
Biol Psychiatry; 2009 Sep; 66(6):554-61. PubMed ID: 19481198
[TBL] [Abstract][Full Text] [Related]
4. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Pavón N; Martín AB; Mendialdua A; Moratalla R
Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
[TBL] [Abstract][Full Text] [Related]
5. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum.
Doucet JP; Nakabeppu Y; Bedard PJ; Hope BT; Nestler EJ; Jasmin BJ; Chen JS; Iadarola MJ; St-Jean M; Wigle N; Blanchet P; Grondin R; Robertson GS
Eur J Neurosci; 1996 Feb; 8(2):365-81. PubMed ID: 8714707
[TBL] [Abstract][Full Text] [Related]
6. Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease.
F Hernández L; Castela I; Ruiz-DeDiego I; Obeso JA; Moratalla R
Mov Disord; 2017 Apr; 32(4):530-537. PubMed ID: 28256089
[TBL] [Abstract][Full Text] [Related]
7. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Soghomonian JJ
Eur J Neurosci; 2006 May; 23(9):2395-403. PubMed ID: 16706847
[TBL] [Abstract][Full Text] [Related]
8. Effect of the metabotropic glutamate antagonist MPEP on striatal expression of the Homer family proteins in levodopa-treated hemiparkinsonian rats.
Jiménez A; Bonastre M; Aguilar E; Marin C
Psychopharmacology (Berl); 2009 Oct; 206(2):233-42. PubMed ID: 19636538
[TBL] [Abstract][Full Text] [Related]
9. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
10. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of Striatal ΔFosB mRNA and FosB mRNA After Different Levodopa Treatment Regimens in a Rat Model of Parkinson's Disease.
Palafox-Sanchez V; Sosti V; Ramirez-García G; Kulisevsky J; Aguilera J; Limón ID
Neurotox Res; 2019 Apr; 35(3):563-574. PubMed ID: 30645726
[TBL] [Abstract][Full Text] [Related]
12. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
Paolone G; Brugnoli A; Arcuri L; Mercatelli D; Morari M
Mov Disord; 2015 Nov; 30(13):1728-38. PubMed ID: 26207892
[TBL] [Abstract][Full Text] [Related]
13. Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
Lane EL; Vercammen L; Cenci MA; Brundin P
Exp Neurol; 2009 Sep; 219(1):355-8. PubMed ID: 19393238
[TBL] [Abstract][Full Text] [Related]
14. AMPK-mediated autophagy pathway activation promotes ΔFosB degradation to improve levodopa-induced dyskinesia.
Liu K; Zhang Z; Xu Y; Wu Y; Lian P; Ma Z; Tang Z; Zhang X; Yang X; Zhai H; Zhang L; Xu Y; Cao X
Cell Signal; 2024 Jun; 118():111125. PubMed ID: 38432574
[TBL] [Abstract][Full Text] [Related]
15. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
[TBL] [Abstract][Full Text] [Related]
16. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
Carlsson T; Winkler C; Burger C; Muzyczka N; Mandel RJ; Cenci A; Björklund A; Kirik D
Brain; 2005 Mar; 128(Pt 3):559-69. PubMed ID: 15659429
[TBL] [Abstract][Full Text] [Related]
17. Neuroinflammation in the generation of post-transplantation dyskinesia in Parkinson's disease.
Lane EL; Soulet D; Vercammen L; Cenci MA; Brundin P
Neurobiol Dis; 2008 Nov; 32(2):220-8. PubMed ID: 18675359
[TBL] [Abstract][Full Text] [Related]
18. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
Perez XA; Zhang D; Bordia T; Quik M
Mov Disord; 2017 Apr; 32(4):538-548. PubMed ID: 28256010
[TBL] [Abstract][Full Text] [Related]
19. Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment.
Cenci MA; Tranberg A; Andersson M; Hilbertson A
Neuroscience; 1999; 94(2):515-27. PubMed ID: 10579213
[TBL] [Abstract][Full Text] [Related]
20. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
Padovan-Neto FE; Ferreira NR; de Oliveira-Tavares D; de Aguiar D; da Silva CA; Raisman-Vozari R; Del Bel E
Neurosci Lett; 2013 Apr; 541():126-31. PubMed ID: 23428503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
